Straits Times Index
3,367.90 +29.33 (+0.88%) S&P 500
5,474.51 -0.58 (-0.01%) Dow
39,152.33 -17.19 (-0.04%) Nasdaq
17,895.23 +15.93 (+0.09%) Bitcoin USD
62,551.75 -194.46 (-0.31%) CMC Crypto 200
1,342.02 -2.49 (-0.19%)
REGN Jul 2024 1070.000 call
| Previous close | 10.95 |
| Open | 9.40 |
| Bid | 5.40 |
| Ask | 14.00 |
| Strike | 1,070.00 |
| Expiry date | 2024-07-19 |
| Day's range | 9.40 - 9.40 |
| Contract range | N/A |
| Volume | |
| Open interest | 184 |
Simply Wall St.Insiders At Regeneron Pharmaceuticals Sold US$26m In Stock, Alluding To Potential Weakness
The fact that multiple Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders offloaded a considerable amount of...
ZacksRegeneron (REGN) Gets Positive CHMP Opinion for Lymphoma Drug
Regeneron (REGN) gets positive CHMP recommendation for odronextamab for the treatment of adults with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma.
BenzingaWhat's Going On With Regeneron Pharmaceuticals Stock On Friday?
On Friday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending conditional approval of odronextamab for relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy. Relapsed/refractory (R/R) follicular lymphoma (FL) refers to cases where FL comes back after initial treatment (relapsed) or
